1Hichman KA,Roberts JM. Rules to Replicat by[J].Cell, 1994,79: 557～562.
2Hunter T,Pines J. Cyclins and Cancer Ⅱ :cyclinD and CDK inhibitors come of age [J]. Cell, 1994, 79:573～582.
3Xiong Y,Stage S,Takeda T et al. Telomerase activity in malignant tumours with dergulation of cell cycle regulator proteins [J]. Genomics, 1992,13: 575.
4Toshiya I,Shigemasa K,West CM et al. P16 overexpression. apotential early indicator of transformation in carcinoma[J]. Genomics, 1992,13: 565.
5Motokura T,Arnold A,Kim YT et al. Underexpression of cyclin dependent kinase (CDK) inhibitors in carcinoma[J]. Biochim Biophys Acta, 1993, 115 (1):63.
6Mannel S, Schuyer M. Sporadic CDKN2 (MTS1/P16INK4 ) gene alteration in humors [J]. Nature,1993,366: 704～707.
7Fujita M. Alteration of P16 and P15 genes in commen epithelial ovarian tumours[J]. Int J Cancer, 1997,74:148～155.
8Ryan A. No evidences exists for methylation intaction of the P16 tumours suppressor gene in ovarian carcinogenesis [J]. Gynecol Oncol, 1998,68 (1): 14 ～ 17.
9Milde L.angusch K. P16/MTS1 inactivation in ovarian carcinomas: high frequencies of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinours[J]. Int J Cancer,1998,79(1):61～65.
10Lisal, McCluskey. Thrombicytosis in woman with carcinoma[J]. Gynecologic Oncology, 1999,72: 82～92.
